Novozymes A/S
XMUN:NZM2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novozymes A/S
XMUN:NZM2
|
DK |
|
Eastwood Bio-Medical Canada Inc
OTC:EWOOF
|
CA |
|
F
|
FirstGroup PLC
OTC:FGROF
|
UK |
|
Great Southern Bancorp Inc
F:GS6
|
US |
|
A
|
Agricultural Bank of China Ltd
DUS:EK7
|
CN |
|
G
|
General Motors Co
XMUN:8GM
|
US |
|
K
|
Kinross Gold Corp
F:KIN2
|
CA |
|
M
|
Mediobanca Banca di Credito Finanziario SpA
DUS:ME9
|
IT |
|
Tokyo Electron Ltd
TSE:8035
|
JP |
|
O
|
Origin Energy Ltd
XBER:ORL
|
AU |
|
J
|
Johnson Controls International PLC
F:TYIA
|
IE |
|
Banco de Sabadell SA
F:BDS
|
ES |
|
W
|
Williams-Sonoma Inc
SWB:WM1
|
US |
|
U
|
Ulta Beauty Inc
LSE:0LIB
|
US |
|
FINEOS Corporation Holdings PLC
F:0M9
|
IE |
Wall St Price Targets
NZM2 Price Targets Summary
Novozymes A/S
According to Wall Street analysts, the average 1-year price target for NZM2 is 62.72 EUR with a low forecast of 51.41 EUR and a high forecast of 78.76 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NZM2's stock price target?
Price Target
62.72
EUR
According to Wall Street analysts, the average 1-year price target for NZM2 is 62.72 EUR with a low forecast of 51.41 EUR and a high forecast of 78.76 EUR.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.
